Skip to main content
  • Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

    OXFORD, England, April 26, 2023 /PRNewswire/ -- Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details